Schizophrenia and oxidative stress: Glutamate cysteine ligase modifier as a susceptibility gene

American Journal of Human Genetics

Volumn 79, Issue 3, 2006, Pages 586-592

  Tosic, Mirjana ^a   Ott, Jurg ^b   Barral, Sandra ^b   Bovet, Pierre ^a   Deppen, Patricia ^a   Gheorghita, Fulvia ^a   Matthey, Marie Louise ^a   Parnas, Josef ^c   Preisig, Martin ^a   Saraga, Michael ^a   Solida, Alessandra ^a   Timm, Sally ^d   Wang, August G ^e   Werge, Thomas ^f   Cuénod, Michel ^a   Do, Kim Quang ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b ROCKEFELLER UNIVERSITY   (United States)

^c HVIDOVRE HOSPITAL   (Denmark)

^d FREDERIKSBERG HOSPITAL   (Denmark)

^e AMAGER HOSPITAL   (Denmark)

^f Mental Health Services CPH   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTAMATE CYSTEINE LIGASE;

ADULT; AGED; ARTICLE; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME SUBUNIT; FEMALE; FIBROBLAST; GENE EXPRESSION REGULATION; GENETIC SUSCEPTIBILITY; HUMAN; MALE; MENTAL DISEASE; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; POSITIVE AND NEGATIVE SYNDROME SCALE; PREFRONTAL CORTEX; PRIORITY JOURNAL; RISK FACTOR; SCHIZOPHRENIA;

EID: 33748676111     PISSN: 00029297     EISSN: None     Source Type: Journal    
DOI: 10.1086/507566     Document Type: Article

References (41)

1. Tsuang MT (2000) Schizophrenia: genes and environment. Biol Psychiatry 47:210-220
2. Harrison PJ, Owen MJ (2003) Genes for schizophrenia? Recent findings and their pathophysiological implications. Lancet 361:417-419
3. Mahadik SP, Mukherjee S (1996) Free radical pathology and antioxidant defense in schizophrenia: a review. Schizophr Res 19:1-17
4. Herken H, Uz E, Ozyurt H, Sogut S, Virit O, Akyol O (2001) Evidence that the activities of erythrocyte free radical scavenging enzymes and the products of lipid peroxidation are increased in different forms of schizophrenia. Mol Psychiatry 6:66-73
5. Marchbanks RM, Ryan M, Day I, Owen M, McGuffin P, Whatley S (2003) A mitochondrial DNA sequence variant associated with schizophrenia and oxidative stress. Schizophr Res 65:33-38
6. Prabakaran S, Swatton J, Ryan M, Huffaker SJ, Huang JJ, Griffin JL, Wayland M, Freeman T, Dudbridge F, Lilley KS, Karp NA, Hester S, Tkachev D, Mimmack ML, Yolken RH, Webster MJ, Torrey EF, Bahn S (2004) Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol Psychiatry 9:684-697
7. Altar CA, Jurata LW, Charles V, Lemire A, Liu P, Bukhman Y, Young TA, Bullard J, Yokoe H, Webster MJ, Knable MB, Brockman JA (2005) Deficient hippocampal neuron expression of proteasome, ubiquitin, and mitochondrial genes in multiple schizophrenia cohorts. Biol Psychiatry 58:85-96
8. Olney JW, Newcomer JW, Farber NB (1999) NMDA receptor hypofunction model of schizophrenia. J Psychiatr Res 33:523-533
9. Coyle JT, Tsai G (2004) NMDA receptor function, neuroplasticity, and the pathophysiology of schizophrenia. Int Rev Neurobiol 59:491-515
10. Meister A, Anderson ME (1983) Glutathione. Annu Rev Biochem 52:711-760
11. Rabinovic AD, Hastings TG (1998) Role of endogenous glutathione in the oxidation of dopamine. J Neurochem 71:2071-2078
12. Kohr G, Eckardt S, Luddens H, Monyer H, Seeburg PH (1994) NMDA receptor channels: subunit-specific potentiation by reducing agents. Neuron 12:1031-1040
13. Choi YB, Lipton SA (2000) Redox modulation of the NMDA receptor. Cell Mol Life Sci 57:1535-1541
14. Do KQ, Lauer CJ, Schreiber W, Zollinger M, Gutteck-Amsler U, Cuenod M, Holsboer F (1995) Gamma-glutamylglutamine and taurine concentrations are decreased in the cerebrospinal fluid of drug-naive patients with schizophrenic disorders. J Neurochem 65:2652-2662
15. Do KQ, Trebesinger A, Kirsten-Kruger M, Lauer C, Dydak U, Hell D, Holsboer F, Boesinger P, Cuenod M (2000) Schizophrenia: glutathione deficit in cerebro spinal fluid and prefrontal cortex in vivo. Eur J Neurosci 12:3721-3728
16. Yao JK, Leonard S, Reddy R (2006) Altered glutathione redox state in schizophrenia. Dis Markers 22:83-93
17. Grima G, Benz B, Parpura V, Cuenod M, Do KQ (2003) Dopamine-induced oxidative stress in neurons with glutathione deficit: implication for schizophrenia. Schizophr Res 62:213-224
18. Castagne V, Rougemont M, Cuenod M, Do KQ (2004) Low brain glutathione and ascorbic acid associated with dopamine uptake inhibition during rat's development induce long-term cognitive deficit: relevance to schizophrenia. Neurobiol Dis 15:93-105
19. Castagne VV, Cuenod M, Do KQ (2004) An animal model with relevance to schizophrenia: sex-dependent cognitive deficits in osteogenic disorder-Shionogi rats induced by glutathione synthesis and dopamine uptake inhibition during development. Neuroscience 123:821-834
20. Steullet P, Neijt H, Cuenod M, Do KQ (2005) Synaptic plasticity impairment and hypofunction of NMDA receptors induced by glutathione deficit: relevance to schizophrenia. Neuroscience 137:807-819
21. Cabungcal J, Nicolas D, Kraftsik R, Cuenod M, Do KQ, Hornung JP (2006) Glutathione deficit during development induces anomalies in the rat anterior cingulate GABAergic neurons: relevance to schizophrenia. Neurobiol Dis 22:624-637
22. Gysin R, Tosic M, Chappuis C, Deppen P, Ruiz V, Bovet P, Cuenod M, Do KQ (2005) Dysregulation of glutamate cysteine ligase in schizophrenia. Paper presented at the 36th Annual Meeting of the Society for Neuroscience, Washington, DC, November 12-16
23. Huang CS, Anderson ME, Meister A (1993) Amino acid sequence and function of the light subunit of rat kidney gamma-glutamylcysteine synthetase. J Biol Chem 268:20578-20583
24. Huang CS, Chang LS, Anderson ME, Meiste: A (1993) Catalytic and regulatory properties of the heavy subunit of rat kidney gamma-glutamylcysteine synthetase. J Biol Chem 268:19675-19680
25. Tsuchiya K, Mulcahy RT, Reid LL, Disteche CM, Kavanagh TJ (1995) Mapping of the glutamate-cysteine ligase catalytic subunit gene (GLCLC) to human chromosome 6p12 and mouse chromosome 9D-E and of the regulatory subunit gene (GLCLR) to human chromosome 1p21-p22 and mouse chromosome 3H1-3. Genomics 30:630-632
26. American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders, 4th ed. American Psychiatric Association, Washington, DC
27. Nurnberger JI Jr, Blehar MC, Kaufmann CA, York-Cooler C, Simpson SG, Harkavy-Friedman J, Severe JB, Malaspina D, Reich T (1994) Diagnostic interview for genetic studies: rationale, unique features, and training: NIMH Genetics Initiative. Arch Gen Psychiatry 51:849-859
28. Nakamura S, Kugiyama K, Sugiyama S, Miyamoto S, Koide S, Fukushima H, Honda O, Yoshimura M, Ogawa H (2002) Polymorphism in the 5′-flanking region of human glutamate-cysteine ligase modifier subunit gene is associated with myocardial infarction. Circulation 105:2968-2973
29. Rodi CP, Darnhofer-Patel B, Stanssens P, Zabeau M, van den Boom D (2002) A strategy for the rapid discovery of disease markers using the MassARRAY system. Biotechniques 32:S62-S69
30. Pulver AE, Mulle J, Nestadt G, Swartz KL, Blouin JL, Dombroski B, Liang KY, Housman DE, Kazazian HH, Antonarakis SE, Lasseter VK, Wolyniec PS, Thornquist MH, McGrath JA (2000) Genetic heterogeneity in schizophrenia: stratification of genome scan data using co-segregating related phenotypes. Mol Psychiatry 5:650-653
31. Arinami T, Ohtsuki T, Ishiguro H, Ujike H, Tanaka Y, Morita Y, Mineta M, et al (2005) Genomewide high-density SNP linkage analysis of 236 Japanese families supports the existence of schizophrenia susceptibility loci on chromosomes 1p, 14q, and 20p. Am J Hum Genet 77:937-944
32. Harada S, Tachikawa H, Kawanishi Y (2001) Glutathione S-transferase M1 gene deletion may be associated with susceptibility to certain forms of schizophrenia. Biochem Biophys Res Commun 281:267-271
33. Pae CU, Yu HS, Kim JJ, Kim W, Lee CU, Lee SJ, Jun TY, Lee C, Paik IH, Serretti A (2004) Glutathione S-transferase M1 polymorphism may contribute to schizophrenia in the Korean population. Psychiatr Genet 14:147-150
34. Pae CU, Kim JJ, Lee SJ, Lee CU, Lee C, Paik IH, Park HR, Yang S, Serretti A (2003) Association study between glutathione S-transferase P1 polymorphism and schizophrenia in the Korean population. Prog Neuropsychopharmacol Biol Psychiatry 27:519-523
35. Shinkai T, Luca VD, Zai G, Shaikh S, Matsumoto C, Arnold PD, Hwang R, King N, Trakalo J, Potapova N, Wong G, Hori H, Wong AH, Ohmori O, Nakamura J, Kennedy JL (2004) No association between the Prol97Leu polymorphism in the glutathione peroxidase (GPX1) gene and schizophrenia. Psychiatr Genet 14:177-180
36. Chen Y, Shertzer HG, Schneider SN, Nebert DW, Dalton TP (2005) Glutamate cysteine ligase catalysis: dependence on ATP and modifier subunit for regulation of tissue glutathione levels. J Biol Chem 280:33766-33774
37. -/-) knockout mouse: novel model system for a severely compromised oxidative stress response. J Biol Chem 277:49446-49452
38. Lewis DA, Hashimoto T, Volk DW (2005) Cortical inhibitory neurons and schizophrenia. Nat Rev Neurosci 6:312-324
39. Kolluri N, Sun Z, Sampson AR, Lewis DA (2005) Lamina-specific reductions in dendritic spine density in the prefrontal cortex of subjects with schizophrenia. Am J Psychiatry 162:1200-1202
40. Cabungcal J, Singer D, Hornung J-P, Cuenod M, Do KQ, Schenk F (2004) Special bias deficit in rats with low glutathione during development: a behaviour model with relevance to schizophrenia. Schizophr Res 67 Suppl 1:118
41. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB Jr, Charney DS (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51:199-214